What is Akero Therapeutics Inc (AKRO) stock price today?

Akero Therapeutics Inc (AKRO) currently trades at $54.65 per share. The stock has a market capitalization of $4.50B and a P/E ratio of —x.

Is AKRO stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Akero Therapeutics Inc has a Smart Value Score of 27/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 1/9 and Altman Z-Score is 4.61.

Is Akero Therapeutics Inc financially healthy?

Akero Therapeutics Inc's Piotroski F-Score is 1/9 (weak financial health). The Altman Z-Score of 4.61 places it in the safe zone.

AKRO

Akero Therapeutics Inc

NASDAQ: AKRO · HEALTHCARE · BIOTECHNOLOGY

$54.65

+0.00% today

Updated 2025-12-09

Market cap

$4.50B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.75

Dividend yield

—

52W range

$32 – $57

Volume

2.9M

Market cap

$4.50B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.75

Dividend yield

—

52W range

$32 – $57

Volume

2.9M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

8.0

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

4.6

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$56.50

+3.39%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

X-Ray snapshot

Strengths

+ Altman Z 4.61 — safe zone

+ Debt/equity 0.00x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-67.17M

Key financials

Revenue Net Income Free Cash Flow

Metric	2021	2022	2023	2024	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-100.74M	$-112.03M	$-151.76M	$-252.06M	$-81.57M
EPS	—	—	—	—	$-3.75
Free cash flow	$-79.68M	$-92.52M	$-145.37M	$-231.11M	$-67.17M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
AKRO	$4.50B	27	4.3	3.0	5.0	8.0	—	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Akero Therapeutics Inc trades at $54.65. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 4.61, it sits in the safe zone.

Frequently asked questions

What is Akero Therapeutics Inc's stock price?

Akero Therapeutics Inc (AKRO) trades at $54.65.

Is Akero Therapeutics Inc overvalued?

Smart Value Score 27/100 (Grade F, Strong Sell).

What is the price target of Akero Therapeutics Inc (AKRO)?

The analyst target price is $56.50, representing +3.4% upside from the current price of $54.65.

Piotroski F-Score?

1/9 — weak financial health.

Altman Z-Score?

4.61 — safe zone.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

akerotx.com

Quick metrics

P/S ratio—

ROE-0.35%

Beta-0.40

50D MA$53.20

200D MA$48.24

Shares out0.08B

Float0.07B

Short ratio—

Avg volume2.9M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

AKRO vs LLY →AKRO vs JNJ →AKRO vs ABBV →Stock screener →